Elagolix + Placebo + Combined Oral Contraceptive
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometriosis
Conditions
Endometriosis
Trial Timeline
Aug 10, 2020 → Jun 1, 2030
NCT ID
NCT04333576About Elagolix + Placebo + Combined Oral Contraceptive
Elagolix + Placebo + Combined Oral Contraceptive is a phase 3 stage product being developed by AbbVie for Endometriosis. The current trial status is active. This product is registered under clinical trial identifier NCT04333576. Target conditions include Endometriosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04333576 | Phase 3 | Active |
Competing Products
20 competing products in Endometriosis